TLR4 and rheumatoid arthritis: Overall, our results identified sGRP78 as a typical immunomodulator in TLR4-dependent inflammation with multiple first reported mechanisms and shed new light on the next-generation therapeutics of chronic inflammatory diseases, including sepsis rheumatoid arthritis, asthma, atherosclerosis, and so on.